00:44 , Aug 9, 2019 |  BC Extra  |  Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

FDA panel for Vascepa means likely delay  Amarin Corp. plc (NASDAQ:AMRN) said it expects FDA to extend the PDUFA date for Vascepa icosapent ethyl to late December from Sept. 28 after the agency scheduled an...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J.   Business: Supply/Service, Agbio/Environmental   Transitioned: Shlomo Yanai to non-executive chairman from non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd. ; he replaces John Miller,...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J.   Business: Supply/Service, Agbio/Environmental   Appointed: Shlomo Yanai as non-executive vice chairman, formerly president and CEO of Teva Pharmaceutical Industries Ltd.  ...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Cambrex, Zeria deal

Cambrex granted Zeria's Tillotts Pharma AG subsidiary exclusive, worldwide rights to use Cambrex's mesalamine-based technology to develop and commercialize products for the treatment of inflammatory bowel disease (IBD). Cambrex is eligible for undisclosed milestones and...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Company News

Cambrex management update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J.   Business: Supply/Service, Agbio/Environmental   Hired: Shawn Cavanagh as EVP and COO, formerly president of Lonza Bioscience at Lonza Group AG  ...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Cambrex, Zenara Pharma deal

Cambrex acquired 51% of Zenara for $20 million. Cambrex said it will acquire the remaining 49% of the company, which will be renamed Cambrex Zenara, in early 2016. Cambrex said the acquisition will allow it...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

KemPharm management update

KemPharm Inc. , North Liberty, Iowa   Business: Neurology, Cardiovascular   Hired: Todd Johnson, a director, as chief commercial officer, formerly director of R&D and controlled substances at Cambrex Corp.  ...
07:00 , May 19, 2008 |  BC Week In Review  |  Company News

Cambrex board of directors update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J.   Business: Supply/Service, Agbio/Environmental   Appointed: Lead director John Miller as chairman  ...
07:00 , May 19, 2008 |  BC Week In Review  |  Company News

Cambrex management update

Cambrex Corp. (NYSE:CBM), East Rutherford, N.J.   Business: Supply/Service, Agbio/Environmental   Promoted: Steven Klosk to president, CEO and a director from EVP and COO; he replaces James Mack, who departed  ...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

Cambrex, ProSyntest A/S deal

Cambrex's Cambrex Karlskoga AB subsidiary will acquire chemical services company ProSyntest for an undisclosed sum. Cambrex said the acquisition will enable the company to better compete in the early clinical stage pharmaceutical custom development market....